Educating Pet Owners On Benefits Of The First Joint Health Super Supplement(TM) for Dogs

LOS ANGELES, June 4, 2015 /PRNewswire/ — Cesar Millan, renowned veterinary joint surgeon Dr. Brian Beale, and Vetz Petz, the company that makes Antinol, announced the release of the first ever super supplement for dogs in the United States. Antinol from Vetz Petz (www.vetzpetz.com) is a revolutionary, 100 percent natural, super supplement that is scientifically proven to support dogs joint health, help age-related discomfort and promote healthy skin.

https://photos.prnewswire.com/prnvar/20150604/221040LOGO

“In all my years as a veterinarian,” Dr. Beale explained, “I have never seen a natural product that works as well, or as fast, as Antinol for joint discomfort. Antinol truly is the first ever super supplement for dogs.”

In clinical studies Antinol proved to work as a super supplement, showing visible improvements for more than 90 percent of dogs within the first 5-10 days – working 50 times faster than regular supplements. A super supplement is one that has a minimum of two independent University or veterinarian registered college studies, and has also been through clinical trials on a minimum of 200 animal patients, with an efficacy rate of greater than 75%. Additionally, a super supplement is 100% natural in all ingredients.

Antinol stands apart from other supplements on the market, where therapies for joint pain have been limited to regular supplements like glucosamine and chondroitin. There have been few clinical studies and little support for their efficacy in relieving joint discomfort.

“I’m using Antinol on my pack and I see a difference in all of them, especially in the older dogs. Their mobility has increased and they are more active than they have been in years,” said Millan. “I rarely endorse a product, but when I find one that works it’s important to get the information out to dog owners.”

The super supplement contains a trademarked ingredient known as PCSO-524, extracted from green mussels from New Zealand. The extract was scientifically developed with patented processes and is 100% natural. The non-active ingredients in Antinol (natural Vitamin E, gelatin, glycerin and olive oil) are also 100% natural. Antinol has been proven to cause no side effects and is suitable for all dog sizes and breeds. A daily dose of Antinol is the perfect supplement to support your dog’s health, happiness and quality of life.

A portion of every sale goes to the Cesar Millan Foundation to lobby for animal welfare and humane education.

About Vetz Petz
Vet Petz U.S.A. is the marketing and distribution company for Vetz Petz, International. Antinol is a 100% natural Super Supplement with patented technology. The supplement is sold in thirteen countries. The company also produces Lyprinol, a human version of the supplement for joint discomfort.

For more information, please visit:
http://www.vetzpetz.com
Facebook.com/vetzpetzusa
Twitter: @vetzpetzusa

About Cesar Millan
Cesar Millan is a best-selling author, a much-in-demand public speaker, a branded pet care product designer/entrepreneur, international star of Nat Geo WILD’s Cesar 911 and original host of the Dog Whisperer. Cesar has co-authored several books as well as generated numerous instructional DVDs and CDs. In 2007, Cesar officially launched The Cesar Millan Foundation, a national nonprofit organization designed to champion worldwide animal advocacy for animals through the support of community education and awareness programs.

Contact Information:
Simone Holzapfel
Managing Director
Shac Communications

0417 656 668
[email protected]

https://photos.prnewswire.com/prnvar/20150604/221041LOGO

Logo – http://photos.prnewswire.com/prnh/20150604/221040LOGO
Logo – http://photos.prnewswire.com/prnh/20150604/221041LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cesar-millan-announces-partnership-with-vetz-petz-antinol-300094642.html

SOURCE Vetz Petz

– Company now offers the industry’s widest range of breast implant options –

DUBLIN, June 4, 2015 /PRNewswire/ — Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA(TM) round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result. The NATRELLE INSPIRA(TM) line of breast implants is designed for women who are interested in increased breast fullness. NATRELLE INSPIRA(TM) breast implants are fuller than Allergan’s round, gel-filled breast implants currently available in the U.S.

Logo – http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

“NATRELLE INSPIRA(TM) is just the latest example of our commitment to breast aesthetics and plastic surgery which will continue into the future,” said Philippe Schaison, President, Allergan Medical.

The FDA approval of NATRELLE INSPIRA(TM) round gel-filled textured breast implants marks the most recent addition to the broad portfolio of currently available NATRELLE(®) products in the U.S. The smooth version of the NATRELLE INSPIRA(TM) round gel-filled breast implants was approved by FDA in February 2015.

“NATRELLE INSPIRA(TM) round gel-filled breast implants have been available in Canada since 2011 and are of particular interest to women seeking to gain breast fullness following pregnancy or undergoing revision or reconstruction surgery,” said Dr. Paul Whidden of MacLeod Trail Plastic Surgery. “Although there are many breast implant options available today, my patients continue to request the combination of fullness and softness NATRELLE INSPIRA(TM) breast implants can provide them.”

NATRELLE INSPIRA(TM) Gel-Filled Breast Implants Important Information

Who may get breast implants (INDICATIONS)?
NATRELLE INSPIRA(TM) Gel-Filled Breast Implants are indicated for women for the following:

    --  Breast augmentation for women at least 22 years old for silicone-filled
        implants. Breast augmentation includes primary breast augmentation to
        increase breast size, as well as revision surgery to correct or improve
        the result of a primary breast augmentation surgery.
    --  Breast reconstruction. Breast reconstruction includes primary
        reconstruction to replace breast tissue that has been removed due to
        cancer or trauma or that has failed to develop properly due to a severe
        breast abnormality. Breast reconstruction also includes revision surgery
        to correct or improve the result of a primary breast reconstruction
        surgery.

IMPORTANT SAFETY INFORMATION
Who should NOT get breast implants (CONTRAINDICATIONS)?

    --  Women with active infection anywhere in their body.
    --  Women with existing cancer or pre-cancer of their breast who have not
        received adequate treatment for those conditions.
    --  Women who are currently pregnant or nursing.

What else should I consider (WARNINGS)?

    --  Breast implants are not lifetime devices, and not necessarily a one-time
        surgery.
    --  Many of the changes to your breasts following implantation cannot be
        undone. If you later choose to have your implant(s) removed and not
        replaced, you may experience unacceptable dimpling, puckering,
        wrinkling, or other cosmetic changes of the breast, which may be
        permanent.
    --  Breast implants may affect your ability to breastfeed, either by
        reducing or eliminating milk production.
    --  Rupture of a silicone-filled breast implant is most often silent and may
        not be detected by you or your doctor. You should have an MRI 3 years
        after your surgery and then every 2 years after that for as long as you
        have your breast implants to determine if rupture is present. If implant
        rupture is noted on an MRI, you should have the implant removed, with or
        without replacement.
    --  With breast implants, a routine screening mammography and
        self-examinations for breast cancer will be more difficult. Ask your
        doctor to help you distinguish the implant from your breast tissue.
        Symptoms of a ruptured implant may be hard knots or lumps surrounding
        the implant or in the armpit, change or loss of size or shape of the
        breast or implant, pain, tingling, swelling, numbness, burning or
        hardening. Tell your doctor of these symptoms and remove ruptured
        implants.
    --  Inform any other doctor who treats you of the presence of your implants
        to minimize the risk of damage to the implants.

What types of conditions require more study (PRECAUTIONS)?
Caution: Notify your doctor if you have any of the following conditions, as the risks of breast implant surgery may be higher:

    --  Autoimmune diseases (for example, lupus and scleroderma).
    --  A weakened immune system (for example, currently taking drugs that
        weaken the body's natural resistance to disease).
    --  Planned chemotherapy following breast implant placement.
    --  Planned radiation therapy to the breast following breast implant
        placement.
    --  Conditions that interfere with wound healing and blood clotting.
    --  Reduced blood supply to breast tissue.
    --  Clinical diagnosis of depression or other mental health disorders,
        including body dysmorphic disorder and eating disorders. Please discuss
        any history of mental health disorders with your surgeon prior to
        surgery. Patients with a diagnosis of depression or other mental health
        disorders should wait for resolution or stabilization of these
        conditions prior to undergoing breast implantation surgery.

What are some complications with breast implants (COMPLICATIONS)?
Key complications are reoperation, implant removal with or without replacement, implant rupture with silicone-filled implants, implant deflation with saline-filled implants, and severe capsular contracture (severe scar tissue around the implant). Other complications include asymmetry, nipple/breast/skin sensation changes, scarring or wrinkling/rippling. Talk to your doctor about other complications.

Talk to your doctor. For more information see the Patient Brochures at www.allergan.com/labeling/usa.htm or call the Allergan Product Support line at 1-800-433-8871.

To report a problem with NATRELLE INSPIRA(TM) Gel-Filled Breast Implants, please call Allergan Product Surveillance at 1-800-624-4261.
NATRELLE INSPIRA(TM) Gel-Filled Breast Implants are available by prescription only.

About Actavis

Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world’s third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Actavis is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Actavis is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

Actavis intends to adopt a new global name – Allergan – pending shareholder approval in 2015.

For more information, visit Actavis’ website at www.actavis.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis’ current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Actavis’ current expectations depending upon a number of factors affecting Actavis’ business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Actavis’ products; risks associated with acquisitions, mergers and joint ventures; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Actavis’ periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

     CONTACTS:                            Investors:

                                          Lisa DeFrancesco

                                          (862) 261-7152


                                          Media:

                                          David Belian

                                          (862) 261-8141


                                          Ember Garrett

                                          (714) 246-3525

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/actavis-announces-fda-approval-of-natrelle-inspira-round-gel-filled-textured-breast-implants-300094519.html

SOURCE Actavis plc

RnRMarketResearch.com adds “Keratitis – Pipeline Review, H1 2015” to its store. The report provides an overview of the Keratitis’s therapeutic pipeline.

DALLAS, June 4, 2015 /PRNewswire-iReach/ — The report “Keratitis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Keratitis with 24 market data tables and 14 figures, spread across 70 pages is available at http://www.rnrmarketresearch.com/keratitis-pipeline-review-h1-2015-market-report.html.

Logo – http://photos.prnewswire.com/prnh/20150604/220811

Keratitis is an inflammation or irritation of the cornea. Keratitis has many causes, including infection, dry eyes, physical and chemical injury, and underlying medical diseases. The most common infectious cause is herpes simplex virus type 1, but it can also be due to varicella zoster. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Keratitis – Pipeline Review, H1 2015 report include: Adamis Pharmaceuticals Corporation, Cellceutix Corporation, Dompe Farmaceutici S.p.A., Lee’s Pharmaceutical Holdings Limited, Peregrine Pharmaceuticals, Inc., RegeneRx Biopharmaceuticals, Inc., Sirnaomics, Inc., The Medicines Company.

Drugs profiles discussed in this report includes brilacidin tetrahydrochloride, C-31G, dipyridamole, IBN-1, LQ-7, moxifloxacin hydrochloride, PGN-632, PIM-45, Recombinant Human Nerve Growth Factor, RGN-259, Small Molecules to Inhibit ATM for Herpes Keratitis, STP-601, targocil, tigecycline. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388754. (This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Featured News & Press Releases cover by this report includes: Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy; Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis; Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin; Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Reasons to buy

    --  Provides strategically significant competitor information, analysis, and
        insights to formulate effective R&D development strategies
    --  Identify emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage
    --  Develop strategic initiatives by understanding the focus areas of
        leading companies
    --  Identify and understand important and diverse types of therapeutics
        under development for Keratitis
    --  Plan mergers and acquisitions effectively by identifying key players of
        the most promising pipeline
    --  Devise corrective measures for pipeline projects by understanding
        Keratitis pipeline depth and focus of Indication therapeutics
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope
    --  Modify the therapeutic portfolio by identifying discontinued projects
        and understanding the factors that drove them from pipeline

Explore more reports on Ophthalmology Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics.

More reports on Pipeline Therapeutics Review 2015:

Peanut Allergy – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Peanut Allergy. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include BioTech Tools s.a., DBV Technologies S.A.., HAL Allergy BV, Immunomic Therapeutics, Inc.

Febrile Neutropenia – Pipeline Review, H1 2015

This report provides a review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesCompanies discussed in this report include Apotex, Inc., Biocon Limited, Coherus BioSciences, Inc., Pfizer Inc., Richter Gedeon Nyrt., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Therapeutic Proteins International, LLC, Xenetic Biosciences plc.

Treatment Resistant Depression – Pipeline Review, H1 2015

The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects. Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type. Companies discussed in this report include Addex Therapeutics Ltd, Amorsa Therapeutics Inc., Edgemont Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Johnson & Johnson, MarcoPolo Pharmaceuticals SA, Otsuka Holdings Co., Ltd.

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research

YOKNEAM, Israel, June 4, 2015 /PRNewswire/ — Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, and Viora Ltd. and Viora Inc., a global manufacturer and distributor of medical aesthetic devices (“Viora”), announced today that they have entered into an agreement to settle Syneron’s patent infringement law suit against Viora in the United States and a business litigation in Israel. As part of the settlement, Viora acknowledged that its Reaction product infringes Syneron’s U.S. patent No. 6,662,054, and acknowledged the validity of the patent. Viora further agreed that for the next 12 years, it will pay Syneron royalties of 7.5% to 15%, depending on the number of systems sold by Viora on all U.S. sales of products that apply vacuum together with radio frequency energy for body contouring, cellulite reduction, skin tightening and circumferential reduction.

http://photos.prnewswire.com/prnvar/20120528/535447

Amit Meridor, Chief Executive Officer of Syneron Medical, said, “We are pleased to reach this settlement that supports the validity of one of our key VelaShape patents and ends the legal activity related to this matter. As a leading innovator in the aesthetic medical device market, we have developed numerous patented technologies and we intend to vigorously defend our intellectual property.”

Eliran Almog, Chief Executive Officer of Viora Inc., said, “Viora is happy to achieve this settlement with Syneron. The end of this dispute will enable us to provide uninterrupted, access to the Reaction(TM) technology, in addition to renewing our focus on our customers, ensuring continued customer and patient satisfaction.”

About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

About Viora
Viora is a market leader in the development of technologically advanced medical aesthetic systems for physicians and aesthetic clinicians worldwide. Dedicated to the research and development of safe and effective aesthetic solutions, Viora provides the highest standard of professional grade solutions. For more information on Viora, visit www.vioramed.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Company’s most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company’s control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.’s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.’s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Logo – http://photos.prnewswire.com/prnh/20120528/535447

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syneron-and-viora-announce-settlement-agreement-of-business-and-patent-litigations-300094293.html

SOURCE Syneron Medical Ltd.

RnRMarketResearch.com adds “Hyperuricemia – Pipeline Review, H1 2015” to its store. The provides an overview of the Hyperuricemia’s therapeutic pipeline.

DALLAS, June 4, 2015 /PRNewswire-iReach/ — The report “Hyperuricemia – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Hyperuricemia , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Hyperuricemia with 25 market data tables and 14 figures, spread across 63 pages is available at http://www.rnrmarketresearch.com/hyperuricemia-pipeline-review-h1-2015-market-report.html .

Photo – http://photos.prnewswire.com/prnh/20150604/220824

Hyperuricemia is an excess of uric acid in the blood. Uric acid is a breakdown product of purines that are part of many foods we eat. While hyperuricemia may indicate an increased risk of gout , the relationship between hyperuricemia and gout is unclear. This report also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.

Companies discussed in this Hyperuricemia – Pipeline Review, H1 2015 report include: AstraZeneca PLC, CymaBay Therapeutics, Inc., Kissei Pharmaceutical Co., Ltd., LG Life Sciences, Ltd., Nippon Chemiphar Co., Ltd., Polaris Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.

Drugs profiles discussed in this report includes arhalofenate, febuxostat, febuxostat XR, JPH-367, KGO-2142, KGO-2173, KUX-1151, LC-350189, NC-2500, pegadricase, RDEA-3170, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia, XEN-102. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388743 . (This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Featured News & Press Releases cover by this report includes: Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat; Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric; Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat; Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat; Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea; May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan; Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67; Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan; Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

List of Tables

Number of Products under Development for Hyperuricemia, H1 2015 8
Number of Products under Development for Hyperuricemia – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Hyperuricemia – Pipeline by AstraZeneca PLC, H1 2015 17
Hyperuricemia – Pipeline by CymaBay Therapeutics, Inc., H1 2015 18
Hyperuricemia – Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19
Hyperuricemia – Pipeline by LG Life Sciences, Ltd., H1 2015 20
Hyperuricemia – Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 21
Hyperuricemia – Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 22
Hyperuricemia – Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 23
Hyperuricemia – Pipeline by Teijin Pharma Limited, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Hyperuricemia Therapeutics – Recent Pipeline Updates, H1 2015 51
Hyperuricemia – Dormant Projects, H1 2015 54
Hyperuricemia – Discontinued Products, H1 2015 55

List of Figures

Number of Products under Development for Hyperuricemia, H1 2015 8
Number of Products under Development for Hyperuricemia – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.

Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research

Company Sets $500,000 Goal to Help Heal Children with Facial Deformities

AGOURA HILLS, Calif., June 4, 2015 /PRNewswire/ — Cydcor, the worldwide leader in outsourced sales services, along with its network of independent sales offices will hold the third-annual “Day of Smiles” fundraiser June 6 to benefit Operation Smile, an international children’s medical charity.

https://photos.prnewswire.com/prnvar/20150604/220959

During the Day of Smiles event, Cydcor and its independent sales offices will raise money by going door-to-door, business-to-business, and fundraising at retail locations across the country. By wearing the same bright blue Operation Smile t-shirts, the staffs of Cydcor and the independent sales offices will unite in their common cause to provide free surgeries to repair cleft lip, cleft palate and other facial deformities for children in need around the world.

Cydcor has partnered with Operation Smile since 2010 and together have helped heal nearly 2,100 smiles by raising more than $500,000 through fundraising efforts and events. They have also helped fund and staff charity medical missions to Brazil, Guatemala and Mexico with Operation Smile, and are planning two additional missions in the coming months.

“Operation Smile is near to our hearts and we are excited to kick off our third-annual Day of Smiles event on June 6,” said Cydcor Chief Operating Officer Vera Quinn. “This year we’re setting the bar high, challenging ourselves to raise $500,000 to help heal the smiles of children in need and help fund missions globally. I’m grateful for the support and dedication of our Cydcor employees and the many independently owned sales offices. We’re honored to be able to support Operation Smile.”

Recently Jim Majeski, President of Cydcor and his wife, philanthropist and entrepreneur Barbara Majeski, received the Founders Circle Award from Operation Smile in recognition of their dedication and contribution to the work of healing smiles worldwide. At the event Barbara Majeski challenged Johnson & Johnson Chairman and CEO Alex Gorsky to match the Cydcor donation if they reach the $500,000 goal. Gorsky graciously accepted the challenge, agreeing to match Cydcor’s fundraising efforts with an additional $500,000 donation from Johnson & Johnson. Gorsky also announced continued support to Operation Smile in the amount of $25 million over the next five years. Johnson & Johnson have been long-time supporters of Operation Smile.

Quinn added, “We’re honored to have Johnson & Johnson partnering with our fundraising efforts. With their matching gift – if we reach our goal – Operation Smile will benefit from $1 million. Johnson & Johnson and Alex Gorsky’s commitment shows that business working together truly can make a profound difference in the lives of others.”

To help support Cydcor’s fundraising efforts, visit www.operationsmile.org/cydcor.

Learn more about Cydcor on Facebook and Twitter, or on the Cydcor blog.

About Cydcor

Cydcor is the leading provider of outsourced, face-to-face sales teams to a diverse client base of companies in a wide range of industries, including telecommunications, office products, retail, energy, and financial services. Serving Fortune 500 and emerging market clients in the business-to-business, residential, and retail channels through in-store marketing initiatives, Cydcor works with a network of more than 350 independently-owned corporate licensee (ICL) sales offices, providing clients access to more than 4,600 sales professionals. The privately-held company is based in Agoura Hills, California. For more information about Cydcor, go to www.cydcor.com.

About Operation Smile

Operation Smile, headquartered in Virginia Beach, Virginia, is an international medical charity with a presence in more than 60 countries, whose global network of thousands of credentialed medical volunteers from more than 80 countries is dedicated to helping improve the health and lives of children. Since its founding in 1982, Operation Smile has provided more than 220,000 free surgical procedures for children and young adults born with cleft lip, cleft palate and other facial deformities. To build long-term sufficiency in resource poor environments, Operation Smile trains doctors and local medical professionals in its partner countries so they are empowered to treat their local communities. Operation Smile also donates medical equipment, supplies and provides year-round medical treatment through its worldwide centers.

    Contact:                     Gail Michalak, Cydcor

                                 805-277-5500

                                 [email protected]

Photo – http://photos.prnewswire.com/prnh/20150604/220959

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cydcor-and-operation-smile-partner-for-third-annual-day-of-smiles-fundraiser-300094405.html

SOURCE Cydcor

In a 6 Week Phase 2a Study, Treatment Showed Statistically Significant and Clinically Meaningful Reduction in A1c Levels

HIGH POINT, N.C., June 4, 2015 /PRNewswire/ — vTv Therapeutics LLC announced today that it has initiated dosing of the AGATA study, a phase 2b clinical trial assessing the efficacy and safety of TTP399, an oral liver-selective Glucokinase Activator (GKA), in patients with type 2 diabetes. In a phase 2a study, TTP399 demonstrated a statistically significant and clinically meaningful reduction in A1c levels compared with placebo after only 6 weeks of dosing, without induction of hypoglycemia or hyperlipidemia and with no induction of insulin secretion in patients with type 2 diabetes.

The AGATA (Add Glucokinase Activator to Target A1c) study is a multi-center, double-blind, placebo- and active-controlled (sitagliptin), study to evaluate the safety and efficacy of TTP399 following six months administration in subjects with type 2 diabetes mellitus on a stable dose of metformin. The trial is designed to demonstrate that TTP399 produces significant and sustainable improvement in glycemic control. Patients enrolled will be randomized to receive placebo, 400 mg or 800 mg of TTP399 or 100mg of sitagliptin once daily for 6 months. The primary efficacy endpoint is change in A1c from baseline to the end of randomized treatment. Key secondary endpoints include changes in lipid parameters and body weight. The AGATA study will be conducted in the United States and is expected to enroll approximately 180 patients.

“Despite the availability of several oral anti-diabetic therapies, a large number of patients with type 2 diabetes do not achieve their recommended A1c target levels. Preclinical and clinical data showed that treatment with TTP399 normalizes A1c without inducing hypoglycemia, therefore convincing us that that TTP399 has the potential to become a new paradigm for the treatment of type 2 diabetes,” said Stephen L. Holcombe, President and CEO, vTv Therapeutics LLC. “Glucokinase (GK) is a physiological glucose-sensor. It is a genetically validated target that has been pursued by the industry for years with many failures due to safety issues and loss of efficacy. We have designed TP399 to only activate GK in the liver and not to interrupt the physiological regulation of GK by the GK regulatory protein. The data we have generated with TTP399 suggests this approach to GK activation will bypass the common pitfalls associated with other GKAs and has positioned TTP399 as the leader in GK Activators currently in development.”

About TTP399
vTv Therapeutics, utilizing its proprietary drug discovery platform, TTP Translational Technology®, has discovered and developed a series of novel, small-molecule, liver-selective GKAs that appear to stimulate the body’s ability to regulate glucose levels without inducing hypoglycemia. TTP399 is the lead clinical candidate and is an oral liver selective compound with a novel binding mode to GK and physiochemical properties that appear to result in functioning only in the liver without interrupting the physiological regulation of GK by the GK regulatory protein.

In a 6-week, multi-center, phase 2a study in type 2 diabetic subjects on stable doses of metformin, TTP399 demonstrated a statistically significant reduction in A1c levels in all TTP399 dose groups compared with placebo, without induction of hypoglycemia or hyperlipidemia and with no induction of insulin secretion in patients with type 2 diabetes. Within the high dose arm of TTP399, approximately 86% of patients with A1c levels <= 7.5% at baseline achieved blood glucose normalization, defined as A1c <= 6.5%, after six weeks of treatment, while 50% of patients with A1c levels <= 8% at baseline achieved normalization after six weeks. For all doses combined, approximately 40% of patients with A1c levels <= 7.5% at baseline achieved blood glucose normalization while 25% of patients with A1c levels <= 8% at baseline achieved normalization. None of the patients receiving placebo reached A1c normalization.

vTv Therapeutics will be presenting pre-clinical data with TTP399 in the following two poster presentations at the 75th American Diabetes Association (ADA)® Scientific Sessions to be held in Boston, Massachusetts from June 5 – 9, 2015:

    --  1168-P: TTP399, a Liver Selective Glucokinase Activator (GKA) that
        Preserves the Physiological Regulation of Glucokinase (GK) by GK
        Regulatory Protein (GKRP)
    --  1271-P: TTP399, a Liver Selective Glucokinase Activator, Increases
        Efficacy of Currently Marketed Therapies for Type 2 Diabetes

About Type 2 Diabetes
Type 2 diabetes is the body’s inability to properly use insulin to control sugar in the bloodstream. It is the most common type of diabetes (representing 90 to 95% of diabetes patients), imposing a growing burden on healthcare systems globally. The goal of maintaining A1c levels below 7.0% is elusive for patients with this life-long disease. In addition to unregulated glucose, diabetics commonly have a variety of co-morbidities, including heart disease, stroke, high blood pressure, blindness, kidney disease, amputations, dental disease, and central and peripheral nervous system impairment.

About vTv Therapeutics LLC
vTv Therapeutics LLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness. vTv’s drug candidates were discovered with its high-throughput drug discovery platform, Translational Technology®, which translates the functional modulation of human proteins into safe and effective medicines. For further company information, visit www.vtvtherapeutics.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vtv-therapeutics-initiates-patient-dosing-in-the-agata-study-a-six-month-phase-2-study-evaluating-ttp399-a-liver-selective-glucokinase-activator-for-the-treatment-of-type-2-diabetes-300094306.html

SOURCE vTv Therapeutics LLC

DUBLIN, June 4, 2015 /PRNewswire/ —

Research and Markets (
http://www.researchandmarkets.com/research/dxrpmh/noninvasive) has announced the
addition of the”Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony,
informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, VisibiliT and Others) –
Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 – 2022″
[http://www.researchandmarkets.com/research/dxrpmh/noninvasive ] report to their offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

The exponential growth of the NIPT market is supported by factors such as high
incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT, and
shifting trend toward child bearing at advanced maternal age (35 years or older). Maternal
age is closely associated with the risk of developing a fetus with chromosomal
abnormalities; hence, rising maternal age is likely to contribute to the increasing
incidence of babies born with chromosomal aneuploidies.

According to Down Syndrome Education (DSE), the incidence rate for Down syndrome is
one in every 830 child births (around 4,700 annually) in the U.S., while the incidence
rate is one in every 920 babies born (around 9,000 annually) in Europe, indicating a large
potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as
amniocentesis and chorionic villus sampling (CVS) are associated with the risk of
miscarriage; hence, these are being replaced with new non-invasive prenatal tests. These
new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and
pose no risk of miscarriage.

North America held the largest share of the global NIPT market in terms of revenue as
well as volume in 2013, accounting for 58.8% and 51.0%, respectively, of the market. Major
players domiciled in the U.S. and relatively high awareness levels about NIPT in North
America are the key factors attributed to the region’s leadership position. In Europe,
market growth largely depends upon increasing penetration of these U.S.-based test
developers and increase in acceptance of these tests.

Japan, Australia, China, and India represent high growth potential markets in
Asia-Pacific. Large population of women preferring late pregnancy is likely to act as a
major driver of the NIPT market in the region. The NIPT market in China is dominated by
two local players: BGI Diagnostics and Berry Genomics. In addition, the recent CFDA
approval for BambniTest would propel the growth of the market in this region.

Sequenom, Inc., Illumina, Inc. (Verinata Health, Inc.), Ariosa Diagnostics, Natera,
Inc., BGI Health, LifeCodexx AG, LabCorp, and Berry Genomics are the key players competing
in the non-invasive prenatal testing market.

These players operate by marketing their proprietary non-invasive prenatal tests by
forming alliances with hospitals, clinical laboratories, and physician offices.

Key Topics Covered:

        Chapter 1 Preface
        Chapter 2 Executive Summary
        Chapter 3 Global Non-Invasive Prenatal Testing Market Overview
        Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume
         (Number of Tests Performed), by Test
        Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume
         (Number of Tests Performed), by Geography
        Chapter 6 Recommendations
        Chapter 7 Company Profiles
        - Ariosa Diagnostics, Inc.
        - BGI Diagnostics
        - Berry Genomics Co., Ltd.
        - Illumina, Inc.
        - Laboratory Corporation of America Holdings (LabCorp)
        - LifeCodexx AG
        - Natera, Inc.
        - Sequenom, Inc.

For more information visit
http://www.researchandmarkets.com/research/dxrpmh/noninvasive

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

    Photo:
    http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets

New home sleep testing device is designed to provide greater ease, confidence, and reliability to clinicians and patients

ANDOVER, Mass., June 4, 2015 /PRNewswire/ — Philips Respironics, a business of Royal Philips (NYSE: PHG AEX: PHIA), today unveiled Alice NightOne, an at home sleep testing system (HST). As the sleep lab industry adjusts to keep pace with the demands of value-based care and changing reimbursement requirements, Alice NightOne enables the efficient identification and treatment of sleep disorder patients. Fully compatible with the Philips Somnolyzer scoring solution, sleep technicians can read the results from the Alice NightOne HST and determine a sleep study score in 50-85 percent less time and with great accuracy*.

http://photos.prnewswire.com/prnvar/20140219/NE67640LOGO-b

“Conventional laboratory-based sleep testing or polysomnography can pose challenges for sleep clinicians and patients, including limited availability and cost,” said Teofilo Lee-Chiong, M.D., Chief Medical Liaison, Philips. “This latest, intuitive testing option allows reliable and accurate diagnosis of sleep disordered breathing that is more accessible and efficient. More importantly, it gives patients the option of having a sleep test in the comfort of their own home, which may improve overall patient experience and drive better outcomes.”

Speeding time to diagnosis and treatment
By eliminating the long wait times for an appointment and discomfort some patients associate with in-lab sleep studies, Alice NightOne can speed the time to diagnosis and treatment. With minimal sensors and intuitive icons, Alice NightOne is easy for patients to set up themselves and limits discomfort while they sleep*. It includes Smart Guide technology that provides step-by-step instructions and feedback to ensure all functions are working properly, reducing the chance of patient error. The device indicates if additional testing may be required before the patient returns the equipment, further streamlining logistics. Along with enabling sleep technicians to identify an appropriate score faster*, Alice NightOne also provides the data necessary to differentiate between obstructive, central and positional sleep apnea.

Connecting care across the sleep patient’s journey
Alice NightOne is the latest in a suite of sleep disorder diagnostic and treatment products from Philips that provide support at every point along the sleep patient’s journey. Philips entire portfolio of sleep solutions is designed to connect care across the health continuum and address the challenges patients and clinicians face in diagnosis, adherence and long-term sleep therapy compliance.

Alice NightOne will be on display at the Philips Respironics booth (#601) at SLEEP 2015, the annual joint meeting of the American Academy of Sleep Medicine and Sleep Research Society. For more information on Philips’ advanced solutions for sleep and respiratory care, visit http://www.respironics.com/ and follow @PhilipsHealth.

For further information, please contact:
Alicia Cafardi
Philips
Tel: +1 724-387-4439
Email: [email protected]

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

* Data on file, Philips internal study

Logo – http://photos.prnewswire.com/prnh/20140219/NE67640LOGO-b

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/philips-debuts-alice-nightone-at-home-sleep-disorder-diagnostic-system-300094171.html

SOURCE Philips Respironics

Features over 2,500 Procedure Codes Performed in an ASC Setting

NEW YORK, June 4, 2015 /PRNewswire-USNewswire/ — The increasing number of surgical procedures that do not require an overnight stay and are being performed in locations other than hospital outpatient facilities are driving demand for cost, utilization and other trend data that facilitate understanding of the Ambulatory Surgery Center (ASC) industry. FAIR Health, an independent, non-profit company with the nation’s largest collection of privately billed medical and dental claims today announced its new FH Ambulatory Surgery Center Benchmarks module, a tool to help meet this need.

FAIR Health products, including the new FH(®) Ambulatory Surgery Center Benchmarks module, are developed from a comprehensive database of more than 18 billion billed medical and dental procedures from commercial insurance claims, with new data continuously added.

The newly launched module will help healthcare stakeholders to analyze the utilization and cost trends associated with the growth in popularity of ASCs and to distinguish them from the utilization and costs of procedures performed in a traditional hospital outpatient setting which are reported in FAIR Health’s FH Outpatient Facility Benchmarks modules. The new module can be used by insurers, employers, plan sponsors and third-party administrators to process out-of-network claims and inform in-network and out-of-network fee schedules. Healthcare professionals, operators of ASCs and public agencies can also use the data in the development of fee schedules as well as to support practice management and strategic planning. Likewise, the data can fuel studies by researchers, policymakers and consultants. By making these data available, FAIR Health is advancing its mission of offering cost transparency to all healthcare stakeholders.

Additional information about the FH Ambulatory Surgery Center Benchmarks module:

    --  Developed from over five million claims for services and procedures
        commonly performed in ASCs
    --  Includes more than 2,500 procedure codes
    --  Benchmarks provided at the state, regional and national level
    --  Updated twice each year

“FAIR Health’s independence and neutrality have contributed to the acceptance of our data and data products by all industry stakeholders,” said Robin Gelburd, President of FAIR Health. “The addition of the FH Ambulatory Surgery Center Benchmarks module will add another dimension to the analysis of the healthcare market and expand our already extensive facility and professional fee database tools.”

About FAIR Health

FAIR Health is a national, independent, nonprofit corporation dedicated to bringing transparency to healthcare costs and health insurance information through comprehensive data products, consumer resources and health systems research support. FAIR Health uses its database of billions of billed medical and dental services to power an award-winning free website (fairhealthconsumer.org). For more information, visit fairhealth.org.

Media Inquiries:
Anayo Afolabi
FAIR Health, Inc.
[email protected]
646-741-9029

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fair-health-introduces-fh-ambulatory-surgery-center-benchmarks-300094223.html

SOURCE FAIR Health

Gold Halo Awards Recognize the Perfect Blend of Profit & Purpose

BEAUMONT, Texas, June 4, 2015 /PRNewswire/ — Jason’s Deli and The University of Texas MD Anderson Cancer Center were honored by the Cause Marketing Forum for their “Strike Through Cancer One Dime at a Time” alliance. They were awarded the 2015 Gold Halo in the Best Health-Related Campaign Category for outstanding efforts to do well by doing good.

When Jason’s Deli, a family-oriented fast casual restaurant in 29 states, realized a number of its employees or their family members recovered from cancer thanks to the care of MD Anderson’s experts, it aligned with the cancer center to create a fundraising campaign based in Jason’s Deli stores.

“As a family business, we take care of our own and support each other. The cancer fight is very personal to us,” said Jason’s Deli CEO and President Joe Tortorice, Jr. “Leading our fundraising efforts by sharing their stories lets everyone know how important it is to support MD Anderson in its mission to eradicate cancer.”

Jason’s Deli featured personal and triumphant stories on its branded bottles of water, of which they sell millions every year. Ten cents from the sale of each water bottle was donated to MD Anderson for cancer research and patient care.

“MD Anderson is extremely grateful to Jason’s Deli for their commitment to raising awareness of the impact that cancer can have on the millions of people touched by the disease,” said DeDe DeStefano, executive director, Corporate Relations at MD Anderson. “‘Strike Through Cancer’ gives millions of people the opportunity to come together and champion the universal fight against cancer.”

This year’s “Strike Through Cancer” alliance continues in Jason’s Deli locations with the new Quinoa Shrimp & Mango Salad, a nutrient-dense entrée co-created with MD Anderson dietitians and cancer prevention researchers. Though cancer is not entirely avoidable, choosing a healthy diet that includes a variety of plant foods may help lower the risk of cancer.

“We congratulate Jason’s Deli and MD Anderson for their success at simultaneously building a better world and the bottom line,” said Cause Marketing Forum President David Hessekiel.

Nearly one hundred programs were entered in this year’s Cause Marketing Halo Award competition.

About the Cause Marketing Halo Awards

Now in their thirteenth year, the Cause Marketing Halo Awards are North America’s highest honor in the field of cause marketing. They are awarded by the Cause Marketing Forum, a Rye, NY-based company that provides business and nonprofit executives with the practical information and connections they need to succeed. Descriptions of all the Cause Marketing Halo Award winners can be found online at www.CauseMarketingForum.com/halo2015.

About Jason’s Deli

A family-owned deli restaurant chain, Jason’s Deli was founded in Beaumont, Texas, in 1976 by Joe Tortorice Jr. and now has more than 250 locations in 29 states. In 2005, Jason’s Deli was the first major restaurant concept to ban artificial trans fats in the U.S. and later became the first to eliminate high-fructose corn syrup. At Jason’s Deli, regardless if you seek gluten-free or vegetarian options, healthy kids’ meals, or if you would like to build your own salad at their famous salad bar, you will be delighted by the bigger choices of better food, from healthy to indulgent. For more information, please visit www.jasonsdeli.com

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation’s top two cancer centers in U.S. News & World Report’s annual “Best Hospitals” survey. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Contact: Meghan Butler, 1-512-657-4548, [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jasons-deli-md-anderson-awarded-gold-halo-by-cause-marketing-forum-for-strike-through-cancer-campaign-300094225.html

SOURCE Jason’s Deli

SEATTLE, June 4, 2015 /PRNewswire/ — Adaptive Biotechnologies announced the publication of a joint study with the Children’s Oncology Group (COG) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) demonstrating that minimal residual disease detected using next-generation sequencing (NGS), available clinically as the clonoSEQ(®) MRD Test through the company’s CLIA-certified laboratory, can more accurately predict relapse and survival compared to multichannel (6-color) flow cytometry in pediatric acute lymphoblastic leukemia (ALL) patients undergoing donor stem cell transplants.

http://photos.prnewswire.com/prnvar/20120103/SF28632LOGO

“The increased sensitivity of next-generation sequencing-based MRD detection allowed identification of patients at significant risk of relapse who would otherwise be defined as MRD-negative with flow cytometry and therefore thought to be at low risk,” said Michael Pulsipher, MD, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, and lead author of the study. “Pre-transplant, NGS-based MRD detection defined good risk patients who could potentially be eligible for less intense treatment approaches, while post-transplant this sensitive method identified MRD-positive patients who may benefit from interventions aimed at preventing relapse.”

Analysis of pre-transplant bone marrow samples from 40 pediatric patients with B-cell ALL found that NGS-based MRD detection predicted relapse and overall survival (OS) significantly better than flow cytometry (p<0.0001 and p=0.003, respectively). The two-year relapse probabilities were 53 percent and 0 percent among NGS-MRD-positive and -negative patients, respectively (p<0.0001), compared to 46 percent and 16 percent among flow MRD-positive and -negative patients (p=0.02). The two-year survival probabilities in MRD-negative patients were 96 percent and 77 percent for NGS and flow cytometry, respectively (p=0.003).

In the post-transplant setting, NGS-MRD detection was also better at predicting relapse than flow cytometry, especially when applied to samples taken early after transplant. One month post-transplant, results from MRD analysis using flow cytometry were not able to discriminate between patients who ultimately relapsed and those who did not, whereas MRD analysis using the NGS-based method showed an estimated relapse probability of 67 percent in positive patients vs. 25 percent in negative patients (p=0.01). The better predictive power of NGS-based MRD detection vs. flow cytometry held at day 100 and 8 months post-transplant. MRD as detected at any point post-transplant using the NGS-based method led to an increase in relapse (hazard ratio: 7.7; p=0.05), independent of other factors.

“This research establishes the potential of next-generation sequencing-based MRD detection in stratifying pediatric ALL patient treatment based on risk of relapse,” said Tom Willis, PhD, Senior Vice President and General Manager, Diagnostic Products, Adaptive Biotechnologies. “Physicians are already using the clonoSEQ Process in the clinical management of their patients with ALL and other lymphoid cancers.”

The study, “IgH-V(D)J NGS-MRD measurement pre- and early post- allo-transplant defines very low and very high risk ALL patients”, by Pulsipher, et al., was published in the May 28 issue of Blood.

About Minimal Residual Disease
Minimal residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells are present at levels undetectable by traditional microscopic examination (also called morphologic examination) of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as the next-generation sequencing utilized by the Adaptive Biotechnologies(®) clonoSEQ MRD Test, are needed for reliable detection of very low levels of MRD.

About the clonoSEQ(®) Process
The Adaptive Biotechnologies clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than other methods of MRD detection, such as ASO-PCR and flow cytometry. The clonoSEQ Process was previously marketed as the ClonoSIGHT(TM) process by Sequenta, Inc., which was acquired by Adaptive Biotechnologies in January 2015.

MRD detection and quantification using the clonoSEQ Process involves two steps that are easily integrated into patient care. In the first step, the clonoSEQ ID Test, cancer cell DNA sequences are identified in a diagnostic sample. In the second step, the clonoSEQ MRD Test, follow-up samples are screened for the previously identified sequences in order to detect residual disease. ClonoSEQ test results are generated in seven days using the company’s CLIA-certified, CAP-accredited laboratory. These results are provided to the ordering physician in a simple, actionable report that shows a patient’s MRD status and level, as well as MRD trends over time via a secure online portal.

About Adaptive Biotechnologies(®
)Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

About the Children’s Oncology Group
The Children’s Oncology Group (COG) is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 9,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer. Today, more than 90 percent of 14,000 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions. COG is part of the NCI’s National Clinical Trials Network (NCTN) and is supported primarily through NCI research grant funding. For more information, please visit http://www.childrensoncologygroup.org.

About the Pediatric Blood and Marrow Transplant Consortium
The Pediatric Blood and Marrow Transplant Consortium is the largest consortium dedicated to research and advocacy for blood and marrow transplantation and cellular therapy studies in the world. Over 80 centers from North America, Australia and New Zealand are full members, with affiliate members throughout the world. The PBMTC is supported through grants from the National Cancer Institute, the National Heart, Lung and Blood Institute, the National Institute of Allergy and Infectious Diseases, and the St. Baldrick’s Foundation. For more information, please visit www.pbmtc.org.

Research reported in this press release was supported by the Children’s Oncology Group, the National Cancer Institute of the National Institutes of Health under award numbers U10CA180886; U10CA180899; U10CA098543; and U10CA098413. COG activities were supported by R01CA1116660. PBMTC activities were supported by 2U01HL069254 and a consortium grant from the St. Baldrick’s Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Logo – http://photos.prnewswire.com/prnh/20120103/SF28632LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/childrens-oncology-grouppediatric-blood-and-marrow-transplant-consortium-study-shows-adaptive-biotechnologies-clonoseq-minimal-residual-disease-mrd-test-superior-to-flow-cytometry-in-predicting-post-transplant-relapse-and-su-300094042.html

SOURCE Adaptive Biotechnologies

ADA, Mich., June 4, 2015 /PRNewswire/ — Amway today announced the opening of the first phase of its new $81 million USD nutrition manufacturing facility in Ada, Michigan, USA, near its world headquarters. The 317,000-square-foot facility will house select manufacturing operations for the company’s Nutrilite(TM) brand of vitamins, minerals and dietary supplements, sold exclusively by Amway Business Owners.

http://photos.prnewswire.com/prnvar/20110314/DE64745LOGO-a

“A growing percent of the population is seeking a supplement that is based in the best of science and the best of nature,” said Amway Chairman Steve Van Andel. “This facility will help to advance our ability to meet that global demand while maintaining the utmost focus on product quality.”

The Michigan-based facility has the capacity to produce more than 1.3 billion soft gel capsules annually and will focus on products such as Nutrilite(TM) Salmon Omega-3.

“This facility features the latest technology and a completely redesigned production process that can yield more than 3.5 million soft gel capsules a day, faster and more efficiently than ever before, while upholding the highest quality standards and processes,” Amway Chief Supply Chain and R&D Officer George Calvert said.

The Michigan facility is one of five new manufacturing facilities slated to open in 2015 for Amway, part of its ongoing $332 million USD manufacturing expansion.

Nutrition sales accounted for 43 percent of Amway’s 10.8 billion USD in 2014 sales.

About Amway
Amway is a $10.8 billion direct selling business based in Ada, Michigan, USA. Top-selling brands for Amway are Nutrilite(TM) vitamin, mineral and dietary supplements, Artistry(TM) skincare and color cosmetics and eSpring(TM) water treatment systems – all sold exclusively by Amway Business Owners. Global sales in 2014 made Amway the #1 direct selling business in the world, according to the Direct Selling News 2015 Global 100. The company’s annual sales figure includes revenue from direct selling operations and other business holdings. For company news, visit globalnews.amway.com.

About Nutrilite
Nutrilite(TM) is the world’s No. 1 selling vitamins and dietary supplements brand* offered exclusively from Amway. The Nutrilite(TM) brand is the only global vitamin and mineral brand to grow, harvest, and process plants on its own certified organic farms.* Farms are located in Washington, Mexico and Brazil.

* Source: Euromonitor International Limited, www.euromonitor.com/amway-claims.

Logo – http://photos.prnewswire.com/prnh/20110314/DE64745LOGO-a

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amway-opens-new-81-million-nutrition-manufacturing-facility-in-michigan-300094025.html

SOURCE Amway

WAYNE, Pa., June 4, 2015 /PRNewswire/ — Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Topline results from this clinical study demonstrated that Egalet-002 did not dose dump or rapidly release the drug in a shorter period of time after being administered with different concentrations of alcohol.

http://photos.prnewswire.com/prnvar/20140219/NY67493LOGO

With almost 30% of individuals living with chronic pain using alcohol to alleviate pain, it is important that extended release opioids do not dose dump when used in the presence of alchohol(1). The primary objective of the study was to evaluate the effect of alcohol administration in varying concentrations on the pharmacokinetic (PK) parameters of an 80 mg dose of Egalet-002 under naltrexone blockade. This study was conducted to characterize the effects of alcohol on Egalet-002, an important safety issue that must be evaluated for an extended-release, long acting opioid product in development.

“Given that individuals who are prescribed opioids to treat their chronic pain may also consume alcohol at the same time, it is important that there is no significant interaction with alcohol for an extended-release opioid product,” said Jeff Dayno, MD, chief medical officer. “The fact that dose dumping does not occur with Egalet-002 in the presence of alcohol provides further evidence of the robustness of Egalet’s Guardian(TM) Technology and further differentiates it from some other opioids which have a black box warning in their label regarding alcohol dose dumping.”

The study examined Cmax, the maximum concentration of a drug, Tmax, the time to maximum plasma concentration, and AUC, the area under the concentration curve, in the Egalet-002 plus 4%, 20% and 40% alcohol arms compared to the Egalet-002 plus water arm. There was no evidence of alcohol dose dumping based on the mean ratios of Cmax and AUC derived from the Egalet-002 plus water arm compared to the Egalet-002 plus alcohol arms. There was also no difference in the median Tmax values between any of the treatment arms.

    1. http://pubs.niaaa.nih.gov/publications/PainFactsheet/Pain_Alcohol.pdf.

Guardian(TM) Technology
Egalet’s Guardian Technology was developed to deliver commonly abused prescription medications in an abuse-deterrent form. The unique plastic injection molding manufacturing process results in abuse-deterrent features designed to resist the most common methods, as well as more rigorous methods, of abuse for morphine and oxycodone — injection and snorting, respectively. The Guardian Technology can be applied broadly across different classes of pharmaceutical products. Egalet’s two lead abuse-deterrent product candidates, Egalet-001 and Egalet-002, are oral formulations of morphine and oxycodone, respectively, developed with the Guardian Technology to make particle size reduction difficult and resist dissolution. They are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative pain treatments. The Company has two approved products: OXAYDO(TM) (oxycodone HCI, USP) tablets for oral use only -CII and SPRIX(®) (ketorolac tromethamine) Nasal Spray. In addition, using Egalet’s proprietary Guardian(TM) Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet’s Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full additional information on Egalet, please visit www.egalet.com.

Please see full prescribing information for OXAYDO at www.oxaydo.com and full prescribing information for SPRIX at www.sprix.com.

Safe Harbor
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; our ability to obtain regulatory approval of our product candidates; ability to have third parties manufacture our products; competitive factors; our ability to find and hire qualified sales professionals; general market conditions; and other risk factors described in Egalet’s filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: [email protected]
Tel: 917-432-9275

Logo – http://photos.prnewswire.com/prnh/20140219/NY67493LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/in-a-clinical-alcohol-interaction-study-egalet-002-an-abuse-deterrent-extended-release-oxycodone-product-candidate-did-not-induce-alcohol-dose-dumping—-an-important-attribute-given-alcohol-use-seen-with-chronic-pain-patients-300093914.html

SOURCE Egalet Corporation

IRVINE, Calif., June 3, 2015 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the Goldman Sachs 36th Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California on Wednesday, June 10, 2015.

http://photos.prnewswire.com/prnvar/20140714/126903

Scott B. Ullem, Edwards Lifesciences’ chief financial officer, is scheduled to speak to conference attendees at 2:00 p.m. PST (5:00 p.m. EST). A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/events.cfm. Following the presentation, an archived version of the webcast will be available on the Edwards investor relations website in the News and Events section, and via the Edwards Lifesciences Investor Relations App for mobile devices.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

Logo – http://photos.prnewswire.com/prnh/20140714/126903

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/edwards-lifesciences-to-present-at-goldman-sachs-36th-annual-global-healthcare-conference-300093734.html

SOURCE Edwards Lifesciences Corporation

DALLAS, June 3, 2015 /PRNewswire/ —

Global and Chinese Insulin Glargine Industry, 2009-2019 Market Research Report
provides key statistics on the market status of the insulin glargine manufacturers and is
a valuable source of guidance and direction for companies and individuals interested in
the industry.

The complete insulin glargine market report spread across 150 pages, talking about 8
companies and supported with 98 tables and figures is now available at
http://www.reportsnreports.com/reports/318312-global-and-chinese-insulin-glargine-industry-2009-2019-market-research-report.html
.

This is a professional and in-depth study on the current state of the global insulin
glargine market with a focus on the Chinese region. The research provides a basic overview
of the industry including its definition, applications and manufacturing technology. Then,
the report explores the international and Chinese major industry players in detail. In
this part, the report presents the company profile, product specifications, capacity,
production value, and 2009-2014 insulin glargine market market shares for each company.
Through the statistical analysis, the report depicts the global and Chinese total market
of Insulin Glargine industry including capacity, production, production value,
cost/profit, supply/demand and Chinese import/export.

The total insulin glargine market is further divided by company, by country, and by
application/type for the competitive landscape analysis. The report then estimates
2014-2019 market development trends of Insulin Glargine industry. Analysis of upstream raw
materials, downstream demand, and current insulin glargine market dynamics is also carried
out. In the end, the report makes some important proposals for a new project of Insulin
Glargine market before evaluating its feasibility. Overall, the report provides an
in-depth insight of 2009-2019 global and Chinese Insulin Glargine market covering all
important parameters.

2019 forecasts are provided for Global and Chinese Capacity, Production, and
Production Value of Insulin Glargine, Cost and Profit Estimation, Market Share of Insulin
Glargine, Supply and Consumption as well as Chinese Import and Export of Insulin Glargine
in this market research report available for purchase at
http://www.reportsnreports.com/Purchase.aspx?name=318312 .

In China, the third generation of insulin is still in promotion period. Since its
price is relatively high, it is mainly used in big cities. The second generation and the
third generation of insulin will take the shape of stagger competition according to
another research report titled Investigation Report on China Insulin Glargine Market,
2010-2019
[http://www.reportsnreports.com/reports/401207-investigation-report-on-china-insulin-glargine-market-2010-2019.html ]
. According to a survey on some sample hospitals in China, the
CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period
of 2014-2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh
(the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7
billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan
& Lee Pharmaceutical. As the patent of Lantus expired in Feb. 2015, the global market
structure is estimated to change in the next few years. On Sep.9, 2014, Eli Lilly and
Company and Boehringer Ingelheim issued a joint statement that the insulin biosimilar
insulin glargine owned by them has been approved to come into market by the EU. On the
other hand, in Chinese market, some local enterprises are also hastening the development
of Lantus’s generic drug.

With the improvement of living standards and the change of life styles in China, the
incidence of diabetes has kept growing and the market size of diabetes drugs has expanded
each year, exceeding CNY 20 billion in 2014 according to CRI’s research. Currently in
China, the second generation of recombinant human insulin is the mainstream of market.
Having reduced the defects of the second generation of insulin and effectively shortened
the length of treatment, the third generation of insulin products is expected to
substitute the second generation gradually. It is predicated that insulin glargine is a
potential product of growth among all three generations of insulin products. This research
provides reference price of insulin glargine in Chinese hospitals by Beijing Gan & Lee,
Aventis Behring GmbH and Tonghua Dongbao. Major manufacturers of China insulin glargine
market mentioned in this research include Gan & Lee Pharmaceuticals, Aventis Behring GmbH
and Tonghua Dongbao Pharmaceutical Co., Ltd. Order a copy of Investigation Report on China
Insulin Glargine Market, 2010-2019 at
http://www.reportsnreports.com/Purchase.aspx?name=401207 .

A third report on Insulin Glargine – Comprehensive patent search covers information
and data on insulin glargine for indications on Treatment of type 1 and type 2 diabetes
mellitus for the control of hyperglycaemia and innovator: Sanofi-Aventis (Lantus, Lantus
Optiset, Lantus Solostar, Optisulin, Optisulin Optiset, Optisulin Solostar). The In-depth
search contains patents from territories that are individually verified and monitored for
changes, including British, German, Spanish, French, US, Canadian, Australian, European,
and PCT patents. This report helps identify patents covering molecule, formulation,
process, use, combinations and more; grouped by patent family and assigned to development
categories based on interpretation of key aspects of the patent claims and manual
filtration of patents so only relevant information is visible. Read more at
http://www.reportsnreports.com/reports/62360-insulin-glargine-comprehensive-patent-search.html
.

Explore more reports on the pharmaceuticals industry at
http://www.reportsnreports.com/market-research/pharmaceuticals .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth
studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com
offers research studies on agriculture, energy and power, chemicals, environment, medical
devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:

Facebook:https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn:www.linkedin.com/company/reportsnreports
[http://www.linkedin.com/company/reportsnreports ]

Twitter:https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest:www.pinterest.com/comeonseo/reportsnreports/
[http://www.pinterest.com/comeonseo/reportsnreports ]

RSS/Feeds:http://www.reportsnreports.com/feed/l-latestreports.xml

        
        Contact:
        Ritesh Tiwari
        TX, Dallas North - Dominion Plaza,
        17304, Preston Road,
        Suite 800, Dallas 75252
        Tel: +1-888-391-5441
        [email protected]

SOURCE ReportsnReports

GARCHING, Germany, June 3, 2015 /PRNewswire/ —

The ITM Group announced today that the European Medicines Agency (EMA) has validated
the company’s Marketing Authorization Application (MAA) of the medicinal product
EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct
use in patients but will be used for radiolabeling of specific carrier molecules for
Targeted Radionuclide Therapy of serious and difficult to treat cancer forms.
EndolucinBeta is the brand name of first-in-class no-carrier-added (n.c.a.) Lutetium-177
and the first medicinal product containing n.c.a. Lutetium-177 seeking Marketing
Authorization in the European Union.

EndolucinBeta as a radiopharmaceutical precursor will be used only for radiolabeling
of carrier molecules such as peptides or antibodies. The nature of the disease to be
treated will be determined by the pharmaceutical substance to be radiolabeled. The
successful MAA validation results in the start of procedure seeking centralized marketing
authorization in the European Union.

About n.c.a. Lutetium-177

Therapeutic n.c.a. Lutetium-177 is a medium energy beta emitter providing a tissue
penetration range that is very effective for selective delivery of therapeutic dose of
ionizing radiation to the tumor cell. In addition, n.c.a. Lutetium-177 emits quantifiable
imagable gamma rays which provide the additional benefit of carrying out simultaneous
scintigraphy making it a theranostically superior radioisotope for Targeted Radionuclide
Therapy.

About the ITM Group

The ITM Group is a privately held group of specialized radiopharmaceutical companies
dedicated to the development of innovative radioisotopes, radiopharmaceuticals and next
generation radiomedical devices. Its commitment to quality, convenience and security of
supply has become an integral part of all products giving them the competitive opportunity
to lead the radiopharmaceutical market. The ITM Group’s innovative platform technologies
also enable manufacturers of conventional therapeutic agents not only to improve the
efficacy of their candidates but also to benefit from ITM Group’s exceptionally advanced
infrastructure and global logistics services.

        
        Contact
        Sebastian Marx
        Head of Sales
        Phone: +49-89-329898618
        Mail: [email protected]

        Steffen Schuster
        Chief Executive Officer (CEO)
        Phone: +49-89-329898622
        Mail: [email protected]

        ITM Isotopen Technologien Muenchen AG
        Aufsichtsratsvorsitzender - Udo J. Vetter, Vorstandsvorsitzender - Steffen Schuster,
         Sitz der Gesellschaft - Lichtenbergstr. 1, 85748 Garching - HG Muenchen - HRB 154944

SOURCE ITM Isotopen Technologien Muenchen AG

Award Reflects the American Society for Aesthetic Plastic Surgery’s Commitment to Advancing the Science, Art and Safe Practice of Plastic Surgery

NEW YORK, June 3, 2015 /PRNewswire-USNewswire/ — Simeon Wall Jr., MD, FACS, a Louisiana-based ABPS board-certified plastic surgeon and director of The Wall Center for Plastic Surgery, was presented with the Tiffany Award for best scientific presentation on S.A.F.E (Separation, Aspiration and Fat Equalization) Liposuction: Evaluating Outcomes and Complications, at The Aesthetic Meeting 2015 in Montreal, Quebec.

http://photos.prnewswire.com/prnvar/20140226/DC72077LOGO

The Tiffany Award is presented by the American Society for Aesthetic Plastic Surgery (ASAPS) on a yearly basis to an individual who provides the best scientific presentation at the annual Aesthetic Meeting. Awards are presented for the prior year’s presentations. Dr. Wall Jr.’s scientific presentation was selected from the thirty presentations made during The Aesthetic Meeting 2014 in San Francisco, California. The winner is selected by Aesthetic Meeting attendees with final approval by the Program Committee and Trustees. The criteria used to choose the winner is based on the topic, its relevance, presentation and delivery.

“The Tiffany Award is one of several initiatives established by the American Society for Aesthetic Plastic Surgery to advance the science, art, and safe practice of aesthetic (cosmetic) plastic surgery among qualified plastic surgeons through medical education and research. The Aesthetic Meeting is an opportunity for plastic surgeons to share their knowledge and experience with their peers for better patient outcomes and this Award is our way of thanking our peers for their contribution to the aesthetic industry,” noted James C. Grotting, MD, President of ASAPS. “I use SAFELipo® in my practice and have found it to be an effective body contouring technique.”

“I’m honored to be a recipient of the prestigious Tiffany Award from The Aesthetic Society for my presentation on SAFELipo®. I think what is resonating with expert plastic surgeons around the world is that SAFELipo is more than just a different way to perform liposuction. It really is comprehensive fat management that includes precise and complete fat removal in conjunction with fat grafting and fat shifting, allowing us to combine all of these elements to create elegant, smooth, and dramatic shapes without the traditional risks of contour deformities or inadequate results we’ve seen with other methods,” explained Simeon Wall, Jr., MD., ASAPS member.

About ASAPS
The American Society for Aesthetic Plastic Surgery (ASAPS), is recognized as the world’s leading organization devoted entirely to aesthetic plastic surgery and cosmetic medicine of the face and body. ASAPS is comprised of over 2,600 Plastic Surgeons; Active Members are certified by the American Board of Plastic Surgery (USA) or by the Royal College of Physicians and Surgeons of Canada and have extensive training in the complete spectrum of surgical and non-surgical aesthetic procedures. International Active Members are certified by equivalent boards of their respective countries. All members worldwide adhere to a strict Code of Ethics and must meet stringent membership requirements.

Website: www.surgery.org
Follow ASAPS on Twitter: www.twitter.com/ASAPS
Become a fan of ASAPS on Facebook: www.facebook.com/AestheticSociety
Join Smart Beauty Guide: www.smartbeautyguide.com
Locate a plastic surgeon in your area: http://www.smartbeautyguide.com/select-surgeon

Logo – http://photos.prnewswire.com/prnh/20140226/DC72077LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/simeon-wall-jr-md-facs-presented-with-the-tiffany-award-for-best-scientific-presentation-on-safelipo-300093540.html

SOURCE American Society for Aesthetic Plastic Surgery

BOCA RATON, Fla., June 3, 2015 /PRNewswire/ — Today the innovative HALO BED(TM), HALO BOOTH(TM) and HALO FX(TM) Halogenerator make their debut in the Dry Salt Therapy (Halotherapy) industry through the exclusive distributor Global Halotherapy Solutions.

Dry Salt Therapy is one of the fastest growing natural wellness therapies in the U.S. Many people with ailments such as asthma and allergies as well as skin conditions like psoriasis and eczema are benefitting greatly. It is also an ideal beauty regimen as it aids with general anti-aging. Now Global Halotherapy Solutions is making it easier than ever for people to experience this type of therapy as well as build their own business. The company has some of the top experts in the world who have extensive knowledge about Salt Therapy. From spas, chiropractors and yoga studios, corporate wellness centers to personal homes, Global Halotherapy Solutions covers it all with their revolutionary Salt Therapy solutions. According to Jo Mayfield owner of Salt Elements in St. Petersburg, FL, “I have already begun working with Global Halotherapy Solutions and their customer service and salt therapy knowledge is second to none.”

Their state-of-the-art HALO BED(TM), HALO BOOTH(TM) and HALO FX(TM) Halogenerator are newly designed with enhanced high-end features that deliver effective and efficient Salt Therapy. Some of these features for the HALO BED(TM) include:

    --  Advanced LED sensory lighting that changes color to provide a tranquil
        and relaxing environment.
    --  New sophisticated stereo system that delivers high-quality sound for a
        soothing auditory experience.
    --  Improved adjustable partition to allow for isolation between respiratory
        and skin therapy.

The convenient and innovative HALO BOOTH(TM) also features the new sophisticated stereo system as well as a more efficient ventilation system. Both products include the advanced HALO FX(TM) Halogenerator which is designed to provide superior operational functionality. This includes an easy programmable display pad as well as a state-of-the art mill and feeder that provide a one-of-a-kind powerful performance. Each of these revolutionary products are ideal for starting a new salt therapy business or adding it on to an any existing business.

European manufacturer Andri Sinka, Managing Partner at Anchor Salt World states, “My team and I are thrilled to have Global Halotherapy Solutions as our new, exclusive distributor in the U.S., Canada and South America as their management team is very experienced at driving significant growth.”

And finally, the company will be creating a charity to give back to leading respiratory condition/disease organizations under the umbrella banner of “Trying H.A.R.D.” (Halotherapy Against Respiratory Diseases) working in partnership with Salt Facility Operators.

If you are interested in learning more about Halotherapy and their state-of-the-art equipment or to become a Sales Partner in the U.S. or Internationally, contact them today!

EDITOR’S NOTE: For more information about Global Halotherapy Solutions please contact Claudia Herchan at 800-806-5422 Ext. 701 or [email protected].

Contact: Global Halotherapy Solutions LLC
Tel: 800-806-5422
Email: [email protected]
Website: www.halotherapysolutions.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-health-and-wellness-company-introduces-3-state-of-the-art-dry-salt-therapy-products-for-various-lung-and-skin-conditions-300092775.html

SOURCE Global Halotherapy Solutions

MONTREAL, June 3, 2015 /PRNewswire/ – Telesta Therapeutics Inc. (TSX:TST; PNK:BNHLF) announced today, that the United States Patent and Trademark Office has issued U.S. Patent No. 9,044,422, which provides intellectual property (IP) protection for Telesta’s Mycobacterium phlei cell wall-nucleic acid complex (MCNA) composition of matter. MCNA is Telesta’s late stage biologic developed for the treatment of high-grade non-muscle invasive bladder cancer in patients who have failed first-line BCG treatment. As previously reported, Telesta is targeting the filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for this therapeutic by the end of June.

Commenting on the issuance of this patent, Dr. Michael Berendt, CEO and Chief Scientist noted: “We are extremely pleased with the issuance of this U.S. composition of matter patent which provides strong IP coverage in the largest and most important commercial market for MCNA. This patent is a key component of our IP portfolio and will provide intellectual property protection for at least 16 years, which is a major advantage as we look forward to commercial approval in 2016.”

This U.S. patent issuance adds to Telesta’s growing portfolio of issued MCNA patents, with recent awards in Australia and South Africa. Telesta is continuing to actively pursue MCNA patent protection across all of the key global pharmaceutical markets.

As part of its ongoing efforts to increase its global visibility and explore multiple strategic opportunities, Telesta will be participating in the 2015 BIO International Convention in Philadelphia from June 15-18, 2015.

About Telesta Therapeutics Inc.

Telesta Therapeutics Inc. is a late stage therapeutics company with near term commercial potential focused on the manufacturing, marketing and licensing/acquisition of proprietary and innovative therapies for the global health market with a focus on MCNA, its late stage uro-oncology therapeutic. The Company’s primary goal is to develop and commercialize products that advance human health and increase shareholder value. For more information, please visit www.telestatherapeutics.com

Except for historical information, this news release may contain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws that reflect the Company’s current expectation regarding future events. Forward-looking statements and information are necessarily based upon a number of estimates and assumptions that, while, considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Readers are cautioned that any such forward-looking statements and information are not guarantees and there can be no assurance that such statements and information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements and information. These forward-looking statements and information involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise. All written and oral forward-looking statements and information attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements.

SOURCE Telesta Therapeutics Inc.

AVT customer introduces 1st automated kiosk for name brand over-the-counter medicines and personal care items.

LOS ANGELES, June 3, 2015 /PRNewswire/ — AVT, Inc. (OTC Markets: AVTC) (www.autoretail.com), a leading manufacturer of automated retailing systems, announced today that their customer, Pharmabox, has introduced the world’s 1(st) automated drugstore. The unique self-service kiosk carries over 140 top selling brand name items typically found in a local pharmacy, Target, CVS, Walgreen’s or Rite Aid-type store.

As published in the South Florida Business Journal, Miami-based Pharmabox worked with AVT to develop a uniquely designed vending machine that features all the latest technologies, including cashless payment systems, interactive screens that display complete product information, and wireless backend management systems. The company calls their system, “A Pharmacy at Your Fingertips.”

According to Wayne Salvino, President of AVT, Inc., there are many opportunities for entrepreneurs within the automated retailing industry. “There has never been a better time for creative-thinking entrepreneurs to start a new business using an automated store distribution model,” Salvino commented. “Virtually anything that can be imagined can be modeled into a fully automated system that can generate sales 24-hours a day.”

The Consumer Healthcare Products Association (CHPA), states that U.S. consumers make 26 trips a year to purchase OTC medicines. “That’s a terrific number of repeat customers, making this a great business model,” Salvino noted.

Pharmabox plans to deploy the innovative units in high-traffic locations throughout the nation, including airports, hotels, business centers, transportation hubs, apartment complexes, college campuses and dormitories, fitness centers, hospitals, sports stadiums, and retail stores.

Salvino said he looks forward to sharing in Pharmabox’s success. “At AVT, one of our key specialties is in taking an idea, applying our expertise, and making an entrepreneur’s dream come true.”

For more information on Pharmabox, visit: www.pharmabox.com

For information on AVT, call (877) 424-3663, or visit: www.autoretail.com.

Media Inquiries:
Innovation Agency
Inov8.us
Info(@)inov8.us

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmabox-introduces-new-concept-with-a-boldly-designed-automated-retailing-system-300093259.html

SOURCE AVT, Inc.

SPRINGFIELD, Mo., June 3, 2015 /PRNewswire/ — National Endeavors, LLC, announces a new, comprehensive and low cost option for potential Medicare Shared Savings Program (MSSP) Accountable Care Organization (ACO) applicants. National Endeavors offers a national strategy for Physicians, Ancillary Providers, Critical Access Hospitals and Independent Physician Associations (IPAs) seeking participation in a MSSP ACO and Chronic Care Management (CCM) program.

Logo – http://photos.prnewswire.com/prnh/20150602/220372LOGO

Photo – http://photos.prnewswire.com/prnh/20150602/220373

MSSP ACOs offer many strategic and financial advantages. While providers seek to better position themselves in a healthcare delivery system that is moving from volume to value, they are evaluating the benefits and costs of participating in an ACO, or even starting their own. For many organizations joining an ACO does not provide the autonomy and flexibility to meet their objectives. Forming an ACO can also be daunting and expensive with smaller organizations facing high administrative staffing costs, a high minimum savings rate (MSR), difficulty with managed care contracting and other similar challenges.

Participants are offered a designated Series of National Endeavors, LLC, an MSSP ACO applicant, for a one-time participation fee and per patient per month fee for consulting and utilization of a cloud-based Patient Health Integrated Tools technology solution. Each Series actively manages their own participants and focuses on their business and clinical objectives, while National Endeavors takes care of the central office ACO infrastructure. Individual Series run their own operations, while collectively governing the national operation. With National Endeavors, members can focus on collaboration and implementing population health initiatives.

Greg Shockey, National Endeavors’ Business Development Director, summarizes the strategy:

“An ACO is an attractive vehicle for strategic alignment among care partners in the transition to a value driven healthcare delivery system. However, for many organizations the challenges of meeting attribution requirements or costly administrative burdens has left them on the sidelines. The goal of National Endeavors is to provide a structure to help get them into the game.”

Additionally, National Endeavors offers a Chronic Care Management solution to its Series participants. Management of chronically ill patients is the cornerstone of effective population health success. The ACO is uniquely positioned to provide an invaluable support service to participants providing this new reimbursable service. The CCM module and comprehensive support may be included as an optional per member per month fee. Benefits include:

    --  Enhanced access to care
    --  Improved population health
    --  Increased revenue
    --  Patients better engaged in self-management
    --  Savings achieved for MSSP

National Endeavors has selected the Health Endeavors Patient Health Integrated Tools (PHIT) platform for its technology infrastructure. PHIT is used by over 40 MSSP ACOs today and has a proven success record.

UPCOMING EVENTS

June 11, 2015 – National Endeavors Webinar
National Endeavors will be hosting a webinar to discuss ACO and CCM opportunities Thursday, June 11, 2015 – 1:00 p.m. Eastern Time
To register, visit: https://attendee.gotowebinar.com/register/92173526074139650

For National Endeavors media contact or questions, please contact:
Greg Shockey, 682-351-7989, Email
or
Steven Henderson, 888-862-0366 x200, Email

National Endeavors
435 E. Walnut
Springfield, MO 65806
www.nationalendeavors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-medicare-aco-participation-opportunity-launched-by-national-endeavors-300093137.html

SOURCE National Endeavors, LLC

First-ever human clinical studies designed to assess the effects of selective p38 alpha kinase inhibition on brain amyloid plaque load and inflammation in patients with Mild Cognitive Impairment (MCI) due to AD or mild AD

CAMBRIDGE, Mass., June 3, 2015 /PRNewswire/ — EIP Pharma LLC (www.eippharma.com) today announced that patient dosing in phase 2 clinical development of VX-745 in Alzheimer’s disease (AD) is underway. VX-745 is an oral brain penetrant, highly selective and potent inhibitor of the alpha isoform of the protein enzyme p38 mitogen activated protein kinase (p38 MAPK alpha).

“Recent human genetic data demonstrate that inflammation is a major driver of disease in patients with symptomatic Alzheimer’s, while the science also indicates the p38 MAPK alpha mechanism could provide a novel approach to effectively treat Alzheimer’s specific inflammatory processes and their effects on neuronal function,” said John Alam, MD, Founder and CEO, EIP Pharma. “VX-745 is a highly selective antagonist of p38 MAPK alpha, achieves excellent brain drug concentrations, and has already been in the clinic. As such, VX-745 provides today a unique opportunity to clinically evaluate the p38 MAPK alpha mechanism in patients with Alzheimer’s disease.”

Two phase 2a clinical studies are being conducted in patients with mild cognitive impairment (MCI) due to AD or mild AD:

    --  Study 302: "A clinical study of two doses of a selective p38 MAP kinase
        inhibitor, VX-745, to evaluate the effects of 12-Week oral twice-daily
        dosing on amyloid plaque load as assessed by Quantitative Dynamic
        11C-PiB positive emission tomography (PET) amyloid scanning". This study
        is being conducted at the Alzheimer's Research Center (ARC), VU Medical
        Center, Amsterdam, Netherlands; with Prof. Philip Scheltens as principal
        investigator.

    --  Study 303: "A Randomized, multiple dose clinical pharmacology study of
        two doses of a selective p38 MAP Kinase inhibitor, VX-745, in patients
        with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) or
        Mild AD". This 6-week treatment study is being conducted at an Early
        Clinical Phase Unit in the Los Angeles region under an IND that was
        cleared in March 2015 by the Division of Neurology Products at the FDA.

“The dynamic PET scanning protocols we have developed significantly reduces the variability that is otherwise seen when measuring brain amyloid plaque levels by standard PET. As a result, drug mechanisms that are active in reducing brain amyloid plaque load in patients would readily be identified with the use of quantitative dynamic PET scanning in clinical studies of the type we are conducting with VX-745,” said Dr. Bart N.M. van Berckel, MD, PhD, of the Nuclear Medicine & PET Research Department at the VU Medical Center.

Further information regarding these clinical trials can be obtained at www.clinicaltrials.gov.

About VX-745 and p38 MAPK alpha
VX-745(1) is an oral small molecule highly specific inhibitor of the intra-cellular enzyme p38 mitogen activated protein kinase alpha (MAPK alpha). In the brain p38 MAPK alpha regulates inflammation through effects on microglia(2), the major immune cell in the central nervous system (CNS). P38 MAPK alpha is also expressed in neurons, where it is involved in memory formation and synaptic plasticity(3). P38 MAPK alpha is increasingly recognized as a highly promising therapeutic target for a broad range of CNS disorders(4), with animal data indicating that p38 MAPK alpha antagonists have the potential to rapidly improve cognitive function(5 6).

VX-745 readily enters the brain, with brain concentrations in pre-clinical studies being approximately two-fold higher than in peripheral blood. VX-745 was discovered by Vertex Pharmaceuticals, Inc. and previously had been clinically evaluated in non-CNS disorders.

VX-745 was licensed from Vertex in 2012 and additional pre-clinical studies were conducted to re-position it as a therapeutic for disorders of the brain.

About EIP Pharma
EIP Pharma, LLC (www.eippharma.com) is a private R&D stage CNS-focused therapeutics company based in Cambridge, Massachusetts. The company is the owner of an issued US patent (#8,697,627, granted April 15 2014; pending worldwide) on the use of VX-745 to reduce existing brain amyloid plaque in patients.

References

    1. Duffy J, et al (2011)   The discovery of VX-745: a novel and selective
       p38 alpha kinase inhibitor.   ACS Med Chem Lett  2, 758-763.
    2. Bachstetter AD et al (2011) Microglial p38alpha MAPK is a key regulator
       of proinflammatory cytokine up-regulation induced by toll-like receptor
       (TLR) ligands or beta-amyloid (Abeta).  J Neuroinflammation 8, 79.
    3. Correa SA, Eales KL (2012) The role of p38 MAPK and its substrates in
       neuronal plasticity and neurodegenerative disease. J Signal Transduct
       2012, 649079
    4. Yasuda S et al (2011).  P38 MAP Kinase inhibitors as potential
       therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 11,
       45-59.
    5. Roy SM et al (2015) Targeting human central nervous system protein
       kinases:  an isoform selective p38 alpha MAPK inhibitor that attenuates
       disease progression in Alzheimer's disease mouse models.  ACS Chem
       Neurosci, 6, 666-80
    6. Alam J (2014) Effects on cognition of a selective p38 MAPK alpha
       inhibitor in aged rats.  Alzheimer's & Dement 10 Supp P922

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eip-pharma-announces-first-patient-dosing-in-phase-2-clinical-studies-of-a-novel-brain-targeted-anti-inflammatory-drug-candidate-vx-745-for-the-treatment-of-alzheimers-disease-ad-300091111.html

SOURCE EIP Pharma LLC

    --  On February 25, 2015, Health Canada approved JINARC(TM) (tolvaptan) as
        the first pharmaceutical treatment available in Canada for patients with
        autosomal dominant polycystic kidney disease (ADPKD). JINARC(TM) was
        discovered in Japan by Otsuka Pharmaceutical and was first approved
        there for the treatment of ADPKD in 2014.
    --  Effective today, JINARC(TM) is now commercially available for use in
        Canada.
    --  JINARC(TM) slows the progression of kidney enlargement in patients with
        ADPKD, which should help protect the kidneys from damage and failure.

MONTREAL, QC, June 3, 2015 /CNW/ – Today, Otsuka Canada Pharmaceutical Inc. announced that JINARC(TM) (tolvaptan), is now commercially available for use in Canada. JINARC(TM) is indicated to slow the progression of kidney enlargement in adults with autosomal dominant polycystic kidney disease (ADPKD).

“ADPKD can have a significant impact on a person’s health and quality of life, and often afflicts many individuals in a family across the generations. Ultimately it leads to kidney failure and the need for kidney transplant or dialysis in most people affected by the disease,” says Dr. Phil McFarlane, nephrologist from Toronto. “With the availability of JINARC(TM), Canadians living with ADPKD and the clinicians who care for them now have an option that can potentially slow cyst growth, delay disease progression, and improve symptom control.”

Approximately, half of polycystic kidney disease (PKD) patients reach end stage renal disease (ESRD) and require renal replacement therapy in the form of dialysis or a kidney transplant by age 54.(1 )According to a recent Canadian survey, the majority of ADPKD patients say the disease has impacted their ability to: complete everyday activities, such as working or spending time with family (66 per cent); travel and go on vacation (58 per cent); and lead a healthy and active lifestyle (56 per cent).(2) Furthermore, on average, two-thirds (67 per cent) of ADPKD patients have other family members who have been diagnosed with the disease.*

“When I was first diagnosed with ADPKD 14 years ago, it was hard for me to accept that there weren’t any treatment options that could slow the progression of my disease,” says Cheri Barton, Ottawa, ON. “With the availability of JINARC(TM), there’s finally hope for our family and for the PKD community.”

Health Canada’s approval was based on the results of the pivotal Phase 3 randomized, double-blind and placebo-controlled TEMPO 3:4 Trial, which is the largest, Phase 3 study conducted to date in adults with ADPKD.(3)

About JINARC(TM) (tolvaptan)

JINARC(TM) was developed over a period of 26 years through the persevering efforts of researchers in Otsuka’s Japanese pharmaceutical research center. Upon discovering a cell signaling pathway that causes renal cysts to proliferate and enlarge,(4) Otsuka launched an effort in 2004 to develop a drug for the disease in conjunction with the world’s leading ADPKD medical specialists. JINARC(TM) is a selective vasopressin V2-receptor antagonist and is indicated to slow the progression of kidney enlargement in patients with ADPKD. Vasopressin is a hormone normally responsible for maintaining water balance by stimulating water re-absorption in the kidney. Vasopressin levels are higher than normal in people with ADPKD. The high level of vasopressin promotes cyst growth, which increases the size of the kidneys.(5) JINARC(TM) works by blocking the effects of vasopressin, which can slow down the rate at which cysts – and therefore kidneys – grow. This should help protect kidneys from damage and failure.(6) JINARC(TM), a twice-daily, oral medication,(7) is now available for eligible patients in Canada as of May 2015. JINARC(TM) is only available through a hepatic safety monitoring and distribution program conducted and maintained by Otsuka Canada Pharmaceutical Inc. (OCPI) and managed in conjunction with patients’ treating physicians. In addition, OCPI is funding a Canadian JINARC(TM) ADPKD patient outcomes registry available to all patients on the treatment.

About ADPKD

ADPKD impacts approximately 35,000 Canadians(8) and affects people regardless of gender, age, race or ethnic origin.(9) ADPKD is the most common, inherited kidney disease and is primarily characterized by the development and expansion of multiple fluid-filled cysts in the kidney, leading to an increase in total kidney volume. As a result of cyst growth, kidneys become significantly enlarged and, over time, kidney function deteriorates and can result in complications that include chronic and acute pain, hypertension and kidney failure.(10) The genetic mutation that causes ADPKD is a dominant trait meaning only one parent needs to be affected for their child to have a 50 per cent chance of inheriting the disease.(11 )

About Otsuka Canada Pharmaceutical Inc.

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing healthcare company that commercializes Otsuka medicines in Canada, with a focus on neuroscience, nephrology, oncology and cardiovascular health. OCPI is dedicated to improving patients’ health and the quality of human life. OCPI was established in 2010, with headquarters in Saint-Laurent, Québec.

About Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

*Given the low incidence population and the small sample size for this hard to reach group, survey results should be interpreted directionally and with caution.

References
___________________
(1) Alam, Ashan and Perrone, Ronald D.,Management of ESRD in patients with autosomal dominant polycystic kidney disease. Advances in Chronic Kidney Disease, Vol 17, No 2. March 2010: pp 164-172.
(2) The “ADPKD – Quality of life patient study” was conducted through an online survey by Vision Critical between November 21, 2014 and February 9, 2015, with 58 Canadian adults who currently have ADPKD. A probability sample of ADPKD patients of the same size would yield a margin of error of +/- 13%.
(3) JINARC(TM) Canadian product monograph. Otsuka Canada Pharmaceutical Inc. Updated: February 23, 2015.
(4) Gattone, VH et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Medicine. 2003: 9 (10): 1323-1326
(5) Ibid.
(6) Ibid.
(7) Ibid.
(8) The Kidney Foundation of Canada. Polycystic kidney disease (PKD). Accessed January 2015. http://www.kidney.ca/page.aspx?pid=329
(9 )The PKD Foundation of Canada. Just diagnosed. Accessed 2015. http://endpkd.ca/learn/learn-about-adpkd/just-diagnosed/
(10) Grantham, Jared J. Does extended-release somatostatin slow the growth of renal cysts in autosomal-dominant polycystic kidney disease? Nature Clinical Practice Nephrology. 2006: 66-67.
(11) The Kidney Foundation of Canada. Polycystic kidney disease (PKD). Accessed January 2015. http://www.kidney.ca/page.aspx?pid=329

SOURCE Otsuka Pharmaceutical Co., Ltd.

Special Report to help health plans reduce billions of dollars in waste; “Digitizing the Manual Workflow of Risk Adjustment” presentation; and dynamic, interactive demo of new solutions designed to help AHIP attendees thrive during ongoing transition will all be available

NASHVILLE, Tenn., June 3, 2015 /PRNewswire/ — (AHIP Institute Booth 1021) — Availity, the nation’s largest real-time health information network, will be providing a wide range of information to help health plans plan for a successful future during the America’s Health Insurance Plan’s (AHIP’s) 2015 Institute, June 3-5, in Nashville, Tenn.

http://photos.prnewswire.com/prnvar/20150602/220268LOGO

Availity released a special report to AHIP Institute attendees, “A multi-billion dollar problem of waste and missed opportunities.” The report identifies billions of dollars in potential savings for health plans and providers regarding admissions, discharge, and transfer (ADT) notification processes as well as authorization requests. According to the report, “the savings associated with automating ADT notifications just for commercial health plans are estimated at nearly $1.9 billion annually.”

ADT notifications and authorizations have been primarily manual processes, and despite other gains in converting to digital systems, this is still mostly the case. While limited automation is taking place, both health plans and providers are still using time-consuming, inefficient, expensive and error-prone manual systems while the complexity of these tasks is growing exponentially.

“While the potential for savings is extraordinary, the report also explains that this is not just about reducing costs,” said Russ Thomas, Availity CEO. “It’s also about missed opportunities to improve the bottom line and care quality.” Availity understands the complexity of this level of automation, and can work with health plans to address their individual rules and criteria for proper authorizations.

Joy Fulton, Availity’s principal of digital health strategies, will share valuable and actionable insights about industry trends and navigating ongoing challenges during her presentation on the 360 Stage on June 4(th) at 9:45 a.m. She will address how to deepen provider engagement, manage risk adjustment, automate the exchange of clinical data and meet compliance mandates.

Availity is also featuring an interactive demo of their recently released ADT and Authorization solution, as well as their new Revenue Program Management solution at Booth 1021. Booth staffers can also provide real-world perspectives on market place developments and realities.

Learn more about Availity health plan solutions at www.availity.com and preregister to receive the full Special Report when it becomes available online at www.availity.com/ADT.

Tweet This: .@Availity to share insights, tools and strategies at #AHIPInstitute Booth 1021. http://bit.ly/1M5arcs #HIT #ADT

About Availity
As an industry-leading, HITRUST-certified health care information technology company, Availity serves an extensive network of health plans, providers, and technology partners nationwide through a suite of dynamic products built on a powerful, intelligent platform. Availity integrates and manages the clinical, administrative, and financial data needed to fuel real-time coordination between providers, health plans, and patients in a growing value-based care environment. Facilitating over 7 million transactions daily, Availity’s ability to provide accurate, timely, and relevant information is vital to the financial success of its clients.

For more information, including an online demonstration, please visit www.availity.com or call 1.800.AVAILITY (282.4548).

Contact:
Matt Schlossberg
Amendola Communications for Availity
[email protected]
630-935-9136

Logo – http://photos.prnewswire.com/prnh/20150602/220268LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/availity-to-share-insights-tools-and-strategies-at-ahip-2015-to-enable-health-plans-to-achieve-long-term-sustainable-success-in-an-evolving-value-based-environment-300093079.html

SOURCE Availity

SAN DIEGO, June 3, 2015 /PRNewswire/ — Sotera(®) Wireless today announced that James Welch, Executive Vice President Product Development and a pioneer in the development of disruptive patient monitoring systems, will lead an educational session at the upcoming Association for the Advancement of Medical Innovation (AAMI) 2015 conference in Denver. The session “It’s Not About Alarms… Lessons Learned in Improving Patient Safety” is an open-invite breakfast symposium on June 8 at 7:00 a.m. Mountain Daylight Time.

Welch intends to highlight what Sotera Wireless has learned through analysis of more than 250,000 hours of multi-parameter continuous surveillance vital signs monitoring data from general care floors and how it is being used to improve patient safety. He will also share details regarding the newly developed cloud-hosted tool to optimize alarm configurations, which aid in reducing alarm fatigue. Mr. Welch will propose a standardized configuration for surveillance monitoring alarm settings and a national performance benchmark based on actual general care floor patient data.

Although alarm fatigue is still a major industry focus, Sotera Wireless is changing the alarm conversation. “No other company that we are aware of has established a multi-parameter national benchmark for alarm performance,” according to Welch. “The data itself is important, but it is what hospitals do with the data that really counts when it comes to patient safety. Our goal at Sotera Wireless is to help clinicians identify early signs of patient deterioration and reduce failure to rescue events. Patients and clinicians on the general care floor are experiencing the benefits of continuous surveillance monitoring with the ViSi Mobile System every day.”

“The ability to use ‘big data’ to manage alarm behavior represents a paradigm shift in our approach, and introduces a new era in patient safety,” according to Dr. Ben Kanter, Chief Medical Officer at Sotera Wireless.

Not attending AAMI Meeting? For more information visit soterawireless.com and stay connected with Sotera Wireless via:
Visi Mobile on Facebook
Visi Mobile on Twitter
Visi Mobile on YouTube

About Sotera Wireless
Sotera Wireless, Inc. is a San Diego based medical device company dedicated to the development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera’s mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement. More information on the company, its ViSi Mobile System and continuous surveillance monitoring can be obtained at soterawireless.com or by sending an email to [email protected]

Sotera(®) and ViSi Mobile(®) are registered trademarks of Sotera Wireless, Inc.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sotera-wireless-to-highlight-companys-advancement-in-surveillance-monitoring-300093059.html

SOURCE Sotera Wireless

Lawsuit Cash Advance Firm announces up-to-date news on major hip settlements in the ongoing litigations involving manufacturers such as BioMet, DePuy, Stryker, and Wright.

PHILADELPHIA, June 3, 2015 /PRNewswire/ — Legal-Bay LLC, The Lawsuit Settlement Funding Company, reported today the most up-to-date news on the ongoing hip litigations and the major hip settlements that have been reached by several major manufacturers. The manufacturers include BioMet, DePuy, Stryker, and Wright. While several high settlements have been reached, certain hip litigations are still ongoing and pending resolution. The following news are the most up-to-date information on each litigation:

    --  BioMet: In February of 2014, Biomet reached a $56 million settlement
        relating to its BioMet M2a 38 and M2a Magnum hip replacement system.
        Settlement awards were about $200K per case that required a revision
        surgery. The multidistrict litigation (MDL) took place in the U.S.
        District Court for the Northern District of Indiana (MDL No. 2391).
    --  Johnson & Johnson/DePuy ASR and Pinnacle Hips: Johnson & Johnson's DePuy
        hip division reached the largest product liability lawsuit settlement in
        U.S. history in late 2013. The company agreed to settle about 7K hip
        lawsuits for approximately $250K per case. The multidistrict litigation
        took place in the U.S. District Court for the Northern District of Ohio
        under Judge David A. Katz (MDL No. 2197). When the ASR litigation is
        completely resolved, it could cost DePuy almost $4 billion, according to
        Bloomberg News. However, there is still time for additional ASR claims
        to be filed as there are approximately 25% of pending cases. The
        Pinnacle hip litigation remains unresolved, with more than 6,500 pending
        claims in the U.S. District Court for the Northern District of Texas
        under Judge Ed Kinkeade (MDL No. 2244). Bellwether trials are set to
        take place this year.
    --  Stryker Corporation: Stryker Corporation has agreed to pay $1.43 billion
        to settle thousands of hip implant lawsuits relating to the Stryker
        Rejuvenate and ABG II Hip Implant. The settlement was announced in
        November of 2014, both in the Bergen County courthouse before Superior
        Court Judge Brian Martinotti and in the U.S. District Court in St. Paul,
        Minnesota (MDL No. 2441). Settlement awards are expected to be in
        amounts of $10K to $600K, depending on the severity of the
        complications.
    --  Wright Medical Technology, Inc.: Approximately 800 claims had already
        been filed by 2014 relating to Wright Medical Technology, Inc.'s
        Conserve and Profemur hip replacements. According to Drug Watch, more
        than 70 cases were pending in a multidistrict litigation in the U.S.
        District Court in the Northern District of Georgia (MDL No. 2329).
        Bellwether trials are set to take place this year.

Logo – http://photos.prnewswire.com/prnh/20140714/126845

Patty Kirby, COO and Head of Client Relations of Legal-Bay, commented on the recent settlements, “We continue to monitor each litigation, not only the pending ones, but the ones that have settled. We have noticed many clients are still waiting for funds on their settled cases, and we are able to provide exceptional pricing for clients who need funds right now, whether on pre-settled or settled deals. Additionally, we are still advising clients who have not retained a law firm that they need to move quickly in order to claim a hip recall award if they have not contacted a lawyer.”

To apply for lawsuit funding or lawsuit money today on your hip case, apply online at: http://lawsuitssettlementfunding.com/stryker-wright-hip-recall-settlement-funding.php

Legal-Bay, a law cash advance company, advises any patients who have suffered complications or metallosis from a hip implant to contact a hip lawyer or hip law firm immediately as the time to file a complaint is limited. Legal-Bay can assist you with obtaining a free legal consultation with a hip lawyer or hip law firm. You can inquire directly with us at: http://lawsuitssettlementfunding.com/contact-us.php

Legal-Bay’s programs are non-recourse lawsuit cash advances, also known as case funding. None of the programs should be considered to be a settlement loan, settlement loans, lawsuit loan, lawsuit loans, pre-settlement loans, or a pre-settlement loan. To learn more about Legal Bay’s lawsuit funding process, visit: http://www.lawsuitssettlementfunding.com/funding-process.php

If you wish to speak to a live agent who can answer any of your lawsuit funding questions, or if you would like to schedule a free consultation with a hip lawyer, call Legal-Bay’s toll-free hotline at: 877.571.0405.

Legal-Bay LLC (as well as their related companies) is not a law firm and cannot provide legal advice on your case, however, Legal-Bay works with lawyers involved in mass tort litigations who can provide you with a free legal consultation at the consumer’s direction.

    Contact:                   Patty Kirby, COO/Head of Client
                               Relations
                               Ph. 877.571.0405 Email:
                               [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/legal-bay-lawsuit-settlement-funding-reports-major-hip-settlements-300091294.html

SOURCE Legal-Bay LLC